Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MHC-I genotype and tumor mutational burden predict response to immunotherapy.

Genome medicine - 19 May 2020

Goodman Aaron M, Castro Andrea, Pyke Rachel Marty, Okamura Ryosuke, Kato Shumei, Riviere Paul, Frampton Garrett, Sokol Ethan, Zhang Xinlian, Ball Edward D, Carter Hannah, Kurzrock Razelle

Abstract excerpt

BACKGROUND: Immune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) (or its ligand (PD-L1)) can stimulate immune responses against cancer and have revolutionized the treatment of tumors. The influence of host germline genetics and its interaction with tumor neoantigens remains poorly defined. We sought to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Histocompatibility Antigens Class I

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 32430031
DOI: 10.1186/s13073-020-00743-4
PMCID: PMC7236948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MHC-I genotype and tumor mutational burden predict response to immunotherapy.PMID 32430031Read ↗

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.Semantic proximity Read ↗

Integrated germline and somatic features reveal divergent immune pathways driving ICB responseSemantic proximity Read ↗

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.Semantic proximity Read ↗

Subclonal landscape of cancer drives resistance to immune therapySemantic proximity Read ↗

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.Semantic proximity Read ↗

Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockadeSemantic proximity Read ↗

Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.Semantic proximity Read ↗

APOBEC3G expression marks a TMB-high, T cell-inflamed tumor state and is associated with response to immune checkpoint blockade in multiple cancer cohortsSemantic proximity Read ↗

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer settingSemantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.